Caribou Biosciences reported a net loss of $41.2 million for the first quarter of 2024, with $345.9 million in cash, cash equivalents, and marketable securities as of March 31, 2024. The company is advancing four clinical-stage programs and expects its current cash to fund operations into Q1 2026.
Advanced CB-010 ANTLER Phase 1 trial for 2L LBCL, with initial dose expansion data to be presented at ASCO 2024.
Expanded into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024.
Progressed four clinical-stage programs for hematologic malignancies and autoimmune diseases, anticipating multiple milestones.
Held $345.9 million in cash, cash equivalents, and marketable securities, expected to fund the current operating plan into Q1 2026.
Caribou Biosciences anticipates several milestones across its clinical programs.
Analyze how earnings announcements historically affect stock price performance